There is alot of significant presentations and bits and pieces...

There is alot of significant presentations and bits and pieces of interest at this important March GBM 2023 conference. Kazia CEO there and about, in the conference.

Once again, instead of low grade contributions on this chatline, it would be good if others made meaningful contributions. So why not look at the agenda here and add something of value /

GBM AGILE under scrutiny

9:30 Panel Discussion: GBM AGILE Goes Worldwide: Taking a Deep Dive Into How Well It Has Worked So
Far & What Promise It Brings With Expansion

• Reflecting on more than 3 years of GBM AGILE - lessons learned to date and plans/goals for the next 3+ years

• Pharma perspectives of participation and stakeholder perspectives

• Learning from an annotated longitudinal database of screens from over 1300 glioblastoma patients

• What progress have we already seen with GBM AGILE so far?

• Conceptually, a ‘master protocol’ requires a standardized trial design across all participating arms, with limited
ability to customize for specific agents. To what extent does that force compromise in the study design? Is there
a risk we end up with a study that isn’t ideally suited to any of its participating drugs?

• As a Bayesian adaptive study, participant companies in GBM AGILE are unable to know much about the ongoing
performance of the study until the study is complete. What are the implications of this, particularly for smaller biotechs?

• GBM AGILE sets pre-defined thresholds for graduation within the study and for successful completion at the end
of the study. How do we balance those thresholds such that we neither take forward ineffective therapies, nor
prematurely discard therapies that may prove beneficial to patients?

James GarnerChief Executive OfficerKazia Therapeutics
David AronsChief Executive Officer National Brain Tumor Society